Endocrinology, Vol 124, 2105-2109, Copyright © 1989 by Endocrine Society

ARTICLES

In the rat, interleukin-1 alpha acts at the level of the brain and the gonads to interfere with gonadotropin and sex steroid secretion

C Rivier and W Vale
Clayton Foundation Laboratories for Peptide Biology, Salk Institute, La Jolla, California 92037.

These studies were designed to investigate a possible effect of the monokine interleukin-1 alpha (Il-1 alpha) on gonadotropins and/or sex steroid secretion. Three putative sites of action were considered: the central nervous system, the pituitary, and the gonads. A central nervous system-mediated mechanism was tested by injecting Il-1 alpha into the lateral ventricle of the brain of castrated rats; this treatment caused a dose-related inhibition of LH secretion, with a minimum effective dose below 0.1 microgram (6.6 pmol) and a maximum effect at 1 microgram (66 pmol). The plateau response was observed 120 min after injection. The possibility that Il-1 alpha might alter pituitary sensitivity was studied by administering 200 ng GnRH, iv, into gonadectomized control rats or rats pretreated with 1 micrograms Il-1 alpha intracerebroventricularly. GnRH induced a comparable increase in the plasma LH levels of both groups of animals. Finally, hypophysectomized immature (24-day-old) female rats were used to determine if we could confirm in vivo that interleukin-1 alpha can act directly at the level of the ovary to interfere with steroidogenesis. In these animals, the sc injection of 20 IU PMSG produced a marked (P less than 0.01) increase in plasma estradiol levels, while the sequential injection of 20 IU PMSG and 1 microgram hCG significantly (P less than 0.01) stimulated progesterone release. The ip administration of 1 microgram Il-1 alpha every 12 h to gonadotropin-treated rats resulted in a significant inhibition of both estradiol and progesterone secretion. The results support possible roles for Il-1 alpha at the levels of the brain and the gonads, but not the pituitary, to inhibit reproductive functions.

This article has been cited by other articles:

				E. Xiao, L. Xia-Zhang, N. Vulliemoz, J. Rivier, and M. Ferin Astressin B, a Corticotropin-Releasing Hormone Receptor Antagonist, Accelerates the Return to Normal Luteal Function after an Inflammatory-Like Stress Challenge in the Rhesus Monkey Endocrinology, February 1, 2007; 148(2): 841 - 848. [Abstract] [Full Text] [PDF]

				N. Pitteloud, J. Villegas, A. A. Dwyer, W. F. Crowley Jr., M. J. McPhaul, and F. J. Hayes Acute Stress Masking the Biochemical Phenotype of Partial Androgen Insensitivity Syndrome in a Patient with a Novel Mutation in the Androgen Receptor J. Clin. Endocrinol. Metab., March 1, 2004; 89(3): 1053 - 1058. [Abstract] [Full Text] [PDF]

				J. M. Kirkwood, C. Bender, S. Agarwala, A. Tarhini, J. Shipe-Spotloe, B. Smelko, S. Donnelly, and L. Stover Mechanisms and Management of Toxicities Associated With High-Dose Interferon Alfa-2b Therapy J. Clin. Oncol., September 1, 2002; 20(17): 3703 - 3718. [Abstract] [Full Text] [PDF]

				J. Dahlgren, C. Nilsson, E. Jennische, H.-P. Ho, E. Eriksson, A. Niklasson, P. Bjorntorp, K. A. Wikland, and A. Holmang Prenatal cytokine exposure results in obesity and gender-specific programming Am J Physiol Endocrinol Metab, August 1, 2001; 281(2): E326 - E334. [Abstract] [Full Text] [PDF]

				C. Y. Williams, T. G. Harris, D. F. Battaglia, C. Viguié, and F. J. Karsch Endotoxin Inhibits Pituitary Responsiveness to Gonadotropin-Releasing Hormone Endocrinology, May 1, 2001; 142(5): 1915 - 1922. [Abstract] [Full Text]

				J. J. Puder, P. U. Freda, R. S. Goland, M. Ferin, and S. L. Wardlaw Stimulatory Effects of Stress on Gonadotropin Secretion in Estrogen-Treated Women J. Clin. Endocrinol. Metab., June 1, 2000; 85(6): 2184 - 2188. [Abstract] [Full Text]

				T. G. Harris, D. F. Battaglia, M. E. Brown, M. B. Brown, N. E. Carlson, C. Viguie, C. Y. Williams, and F. J. Karsch Prostaglandins Mediate the Endotoxin-Induced Suppression of Pulsatile Gonadotropin-Releasing Hormone and Luteinizing Hormone Secretion in the Ewe Endocrinology, March 1, 2000; 141(3): 1050 - 1058. [Abstract] [Full Text] [PDF]

				D. F. Battaglia, H. B. Krasa, V. Padmanabhan, C. Viguié, and F. J. Karsch Endocrine Alterations That Underlie Endotoxin-Induced Disruption of the Follicular Phase in Ewes Biol Reprod, January 1, 2000; 62(1): 45 - 53. [Abstract] [Full Text]

				M. A. Sortino, F. Condorelli, C. Vancheri, and P. L. Canonico Tumor Necrosis Factor-{alpha} Induces Apoptosis in Immortalized Hypothalamic Neurons: Involvement of Ceramide-Generating Pathways Endocrinology, October 1, 1999; 140(10): 4841 - 4849. [Abstract] [Full Text]

				G. Van den Berghe, F. de Zegher, and R. Bouillon Acute and Prolonged Critical Illness as Different Neuroendocrine Paradigms J. Clin. Endocrinol. Metab., June 1, 1998; 83(6): 1827 - 1834. [Full Text]

				B. MARCHETTI, F. GALLO, Z. FARINELLA, C. TIROLO, N. TESTA, C. ROMEO, and M. C. MORALE Luteinizing Hormone-Releasing Hormone Is a Primary Signaling Molecule in the Neuroimmune Network Ann. N.Y. Acad. Sci., May 1, 1998; 840(1): 205 - 248. [Abstract] [Full Text] [PDF]

				R. E. Nappi and S. Rivest Effect of Immune and Metabolic Challenges on the Luteinizing Hormone-Releasing Hormone Neuronal System in Cycling Female Rats: An Evaluation at the Transcriptional Level Endocrinology, April 1, 1997; 138(4): 1374 - 1384. [Abstract] [Full Text] [PDF]

				A. V. Turnbull and C. Rivier Inhibition of Gonadotropin-Induced Testosterone Secretion by the Intracerebroventricular Injection of Interleukin-1{beta} in the Male Rat Endocrinology, March 1, 1997; 138(3): 1008 - 1013. [Abstract] [Full Text] [PDF]